Logo image of RHLD

RESOLUTE HOLDINGS MANAG (RHLD) Stock Fundamental Analysis

NASDAQ:RHLD - Nasdaq - US76134H1014 - Common Stock - Currency: USD

43.33  +0.08 (+0.18%)

After market: 43.33 0 (0%)

Fundamental Rating

1

Overall RHLD gets a fundamental rating of 1 out of 10. We evaluated RHLD against 82 industry peers in the Professional Services industry. The financial health of RHLD is average, but there are quite some concerns on its profitability. RHLD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

RHLD had negative earnings in the past year.
RHLD Yearly Net Income VS EBIT VS OCF VS FCFRHLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 20M 40M 60M 80M 100M

1.2 Ratios

With a Return On Assets value of -1.09%, RHLD is not doing good in the industry: 67.07% of the companies in the same industry are doing better.
The Return On Equity of RHLD (-26.31%) is worse than 78.05% of its industry peers.
Industry RankSector Rank
ROA -1.09%
ROE -26.31%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RHLD Yearly ROA, ROE, ROICRHLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 -2K -4K -6K -8K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RHLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RHLD Yearly Profit, Operating, Gross MarginsRHLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 10 20 30 40 50

4

2. Health

2.1 Basic Checks

RHLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RHLD Yearly Shares OutstandingRHLD Yearly Shares OutstandingYearly Shares Outstanding 2024 2M 4M 6M 8M
RHLD Yearly Total Debt VS Total AssetsRHLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2024 5K 10K 15K 20K

2.2 Solvency

Based on the Altman-Z score of 1.72, we must say that RHLD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.72, RHLD is doing worse than 69.51% of the companies in the same industry.
A Debt/Equity ratio of 20.38 is on the high side and indicates that RHLD has dependencies on debt financing.
RHLD has a worse Debt to Equity ratio (20.38) than 91.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 20.38
Debt/FCF N/A
Altman-Z 1.72
ROIC/WACCN/A
WACCN/A
RHLD Yearly LT Debt VS Equity VS FCFRHLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2024 -200K -400K -600K

2.3 Liquidity

A Current Ratio of 3.61 indicates that RHLD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 3.61, RHLD belongs to the best of the industry, outperforming 91.46% of the companies in the same industry.
A Quick Ratio of 2.64 indicates that RHLD has no problem at all paying its short term obligations.
RHLD's Quick ratio of 2.64 is amongst the best of the industry. RHLD outperforms 85.37% of its industry peers.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 2.64
RHLD Yearly Current Assets VS Current LiabilitesRHLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 200K 400K 600K 800K

0

3. Growth

3.1 Past

RHLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.69%, which is quite impressive.
Looking at the last year, RHLD shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)26.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RHLD Yearly Revenue VS EstimatesRHLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 100M 200M 300M

0

4. Valuation

4.1 Price/Earnings Ratio

RHLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RHLD Price Earnings VS Forward Price EarningsRHLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RHLD Per share dataRHLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for RHLD!.
Industry RankSector Rank
Dividend Yield N/A

RESOLUTE HOLDINGS MANAG

NASDAQ:RHLD (7/25/2025, 4:01:42 PM)

After market: 43.33 0 (0%)

43.33

+0.08 (+0.18%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)05-12 2025-05-12
Earnings (Next)N/A N/A
Inst Owners43.47%
Inst Owner Change-0.14%
Ins Owners1.81%
Ins Owner Change-202.22%
Market Cap369.60M
AnalystsN/A
Price TargetN/A
Short Float %6.75%
Short Ratio4.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 41.67
P/tB 41.67
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.04
TBVpS1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.09%
ROE -26.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 20.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 2.64
Altman-Z 1.72
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-102.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A